Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants.

Autor: Oh W; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Stevenson DK; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Tyson JE; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Morris BH; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Ahlfors CE; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Bender GJ; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Wong RJ; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Perritt R; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Vohr BR; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Van Meurs KP; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Vreman HJ; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Das A; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Phelps DL; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., O'Shea TM; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA., Higgins RD; Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA.
Jazyk: angličtina
Zdroj: Acta paediatrica (Oslo, Norway : 1992) [Acta Paediatr] 2010 May; Vol. 99 (5), pp. 673-678. Date of Electronic Publication: 2010 Jan 25.
DOI: 10.1111/j.1651-2227.2010.01688.x
Abstrakt: Objectives: To assess the influence of clinical status on the association between total plasma bilirubin and unbound bilirubin on death or adverse neurodevelopmental outcomes at 18-22 months corrected age in extremely low birth weight infants.
Method: Total plasma bilirubin and unbound bilirubin were measured in 1101 extremely low birth weight infants at 5 +/- 1 days of age. Clinical criteria were used to classify infants as clinically stable or unstable. Survivors were examined at 18-22 months corrected age by certified examiners. Outcome variables were death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss, and death prior to follow-up. For all outcomes, the interaction between bilirubin variables and clinical status was assessed in logistic regression analyses adjusted for multiple risk factors.
Results: Regardless of clinical status, an increasing level of unbound bilirubin was associated with higher rates of death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss and death before follow-up. Total plasma bilirubin values were directly associated with death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss, and death before follow-up in unstable infants, but not in stable infants. An inverse association between total plasma bilirubin and death or cerebral palsy was found in stable infants.
Conclusions: In extremely low birth weight infants, clinical status at 5 days of age affects the association between total plasma bilirubin and death or adverse neurodevelopmental outcomes at 18-22 months of corrected age. An increasing level of UB is associated a higher risk of death or adverse neurodevelopmental outcomes regardless of clinical status. Increasing levels of total plasma bilirubin are directly associated with increasing risk of death or adverse neurodevelopmental outcomes in unstable, but not in stable infants.
Databáze: MEDLINE